Inogen Rove 6
Payments companies reported to CMS as associated with Inogen Rove 6. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Inogen Rove 6, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Inogen Rove 6
These are the largest totals companies reported as associated with Inogen Rove 6. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Heather Giannini | Marlton, NJ | Pulmonary Disease | $18,885.15 |
| Joao Deandrade | Nashville, TN | Pulmonary Disease | $12,278.64 |
| Wassim Labaki | Ann Arbor, MI | Pulmonary Disease | $11,022.06 |
| Jerry Krishnan | Chicago, IL | Pulmonary Disease | $9,721.02 |
| Ayodeji Adegunsoye | Chicago, IL | Pulmonary Disease | $8,723.50 |
| Colin Swenson | Atlanta, GA | Pulmonary Disease | $5,819.81 |
| Andrew Gangemi | Philadelphia, PA | Internal Medicine | $4,786.47 |
| Kunal Jakharia | Chapel Hill, NC | Internal Medicine | $1,047.17 |
Prescribed Inogen Rove 6?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.